|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:clinicalTrialPhase
|
Phase 3 (tab-cel)
|
|
gptkbp:collaboratesWith
|
gptkb:Fujifilm_Diosynth_Biotechnologies
gptkb:MSD_(Merck_&_Co.)
|
|
gptkbp:focus
|
immunotherapy
gene therapy
|
|
gptkbp:foundedYear
|
2012
|
|
gptkbp:founder
|
Isaac Ciechanover
|
|
gptkbp:headquartersLocation
|
gptkb:South_San_Francisco,_California,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atara Biotherapeutics
|
|
gptkbp:industry
|
gptkb:biotechnology
|
|
gptkbp:notableAchievement
|
first allogeneic T-cell immunotherapy approved in Europe (tab-cel)
|
|
gptkbp:notableProduct
|
tab-cel (tabelecleucel)
|
|
gptkbp:numberOfEmployees
|
200-500
|
|
gptkbp:products
|
allogeneic T-cell immunotherapies
|
|
gptkbp:publiclyTraded
|
true
|
|
gptkbp:servesArea
|
global
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
gptkb:ATRA
|
|
gptkbp:therapeuticArea
|
infectious diseases
oncology
autoimmune diseases
|
|
gptkbp:website
|
https://www.atarabio.com/
|
|
gptkbp:bfsParent
|
gptkb:Beth_Seidenberg
gptkb:South_San_Francisco,_California,_USA
|
|
gptkbp:bfsLayer
|
7
|